iQur (formerly HepCgen) was established to develop novel approaches to the diagnosis and treatment of liver disorders, particularly Hepatitis C and liver fibrosis.
The Company has several objectives:
- To build a novel service based on the effective diagnosis of Hepatitis C
- To pursue two drug development strategies for novel therapies to combat Hepatitis C
- To develop novel, non-invasive methods of diagnosing liver fibrosis
|
As at 31 Dec 2012 |
IP Group holding |
IP Venture Fund* holding |
17.5% |
2.8% |
| |
*IP Group has a 10%
economic interest in IP
Venture Fund |
Holdings represent undiluted beneficial equity interest excluding debt